DC:ALK-B ALK-Abelló A/S

ALK-Abelló A/S, a pharmaceutical company, develops, manufactures, and sells a range of products for the diagnosis, prevention, and treatment of respiratory allergy and allergic asthma in Europe, North America, and internationally. The company offers allergy immunotherapy products in the form of injections, as well as sublingual drops and tablets for the treatment of various allergies, including house dust mite, grass, tree, ragweed, and Japanese cedar. It also provides adrenaline auto-injectors for the treatment of severe allergic reactions; and manufactures products used in the diagnosis of allergies. The company markets its products primarily under the ACARIZAX/ODACTRA, MITICURE, RAGWITEK, and GRAZAX/GRASTEK brand names. ALK-Abelló A/S was founded in 1923 and is headquartered in Hørsholm, Denmark.This company has ADRs that trade in the U.S. as the symbol AKABY.

102.00 EUR
As of 03/23/2023

---

Security Information

---

Category1:  Global Equity
Category2:  Common stocks
Category3:  Developed markets ex-US
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Denmark
Country of incorporation:  Denmark
IPO date:  03/10/2000
Stock exchange:    Omx Nordic Exchange Copen
Exchange country:   Denmark
Market cap:   29,358,399,488 EUR
Current dividend yield:   0.00%
Sedol:      B0VL7C2